Condition: Relapsed Adult AML · Primary Refractory Acute Myeloid Leukemia · High Risk Acute Myeloid Leukemia · Sponsor: Massachusetts General Hospital
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
This description comes directly from the study's public registry record.
Areej El-Jawahri, MD · 617-724-4000 · ael-jawahri@partners.org
Chardria S Trotter, MPH, MBA · CTrotter@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| University of Alabama - Birmingham | Birmingham, Alabama, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| University of Colorado Denver I Anschutz Medical Campus | Denver, Colorado, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Evanston, Illinois, United States | Recruiting |
| Indiana University | Bloomington, Indiana, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05237258